---
title: "HUA MEDICINE announced the completion of two clinical studies"
description: "HUA MEDICINE's CEO Chen Li announced at the Pharmaceutical Innovation and Investment Conference that the company has completed two clinical studies: the first is the SENSITIZE 2 study in collaboration"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/221071520.md"
published_at: "2024-11-30T10:04:21.000Z"
---

# HUA MEDICINE announced the completion of two clinical studies

> HUA MEDICINE's CEO Chen Li announced at the Pharmaceutical Innovation and Investment Conference that the company has completed two clinical studies: the first is the SENSITIZE 2 study in collaboration with The Chinese University of Hong Kong, which shows that high glucose clamp technology can significantly improve insulin secretion in individuals with abnormal glucose tolerance; the second is the Phase I clinical study of the second-generation glucokinase activator in the United States, which indicates that the exposure level of HM-002-1005 tablets is comparable to that of sitagliptin tablets. The company will optimize the formulation and conduct multiple ascending dose clinical development

HUA MEDICINE's CEO Chen Li announced today at the 9th Pharmaceutical Innovation and Investment Conference the completion of two clinical studies: First, the SENSITIZE 2 study, conducted in collaboration with Professor Juliana Chan's team from The Chinese University of Hong Kong, has been successfully completed. The results show that "using high glucose clamp technology, a single dose of Dapagliflozin restores GK enzyme activity and significantly improves the second-phase insulin secretion and β-cell glucose sensitivity in individuals with glucose tolerance abnormalities"; Second, the Phase I clinical study of the second-generation glucose kinase activator conducted in the United States has been completed, with results indicating that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to that of Dapagliflozin tablets at 75mg BID. The company will further optimize the formulation and conduct multiple ascending dose clinical development of the second-generation GKA in China and the United States to achieve better therapeutic effects. Note: The second-generation GKA is the prodrug of HUA MEDICINE's new diabetes drug Dapagliflozin

### Related Stocks

- [02552.HK - HUA MEDICINE-B](https://longbridge.com/en/quote/02552.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 拜切公司｜8-K：2025 财年 Q4 营收 2.64 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276442357.md) |
| Guardant Health｜10-K：2025 财年营收 9.82 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276387081.md) |
| 港股异动：博耳电力大涨 41.79%，资金流入显著，市场情绪高涨但波动性需警惕 | 博耳电力大涨 41.79%；宁德时代跌 0.56%，成交额达到 3.52 亿港币；汇聚科技跌 1.52%，成交额达到 1.07 亿港币；沃尔核材跌 2.31%，成交额达到 29.56 百万港币；中伟新材跌 0.39%，市值达到 371 亿港 | [Link](https://longbridge.com/en/news/276413379.md) |
| Newamsterdam Pharma｜8-K：2025 财年营收 22.5 百万美元 |  | [Link](https://longbridge.com/en/news/276224188.md) |
| 艾可菲｜10-K：2025 财年营收 60.75 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276382538.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.